Abstract
Purpose
To report the 1-year outcomes of a prospective phase II study on hypofractionated whole-breast intensity-modulated radiotherapy (IM-WBRT) with a simultaneous integrated boost (SIB) to the tumor bed delivered with static ports of tomotherapy (TomoDirect) (TD).
Methods
A prospective cohort of 82 patients was enrolled between 2011 and 2012. Treatment schedule consisted of 45 Gy/20 fractions to the whole breast and 50 Gy/20 fractions to the surgical bed delivered concomitantly with TD over 4 weeks. A one-armed optimal two-stage Simon’s design was selected to test the hypothesis that treatment modality under investigation would decrease acute skin toxicity over historical data using conventional fractionation and sequential boost. Primary endpoint was acute skin toxicity. Secondary endpoints included late toxicity, cosmesis, quality of life and local control.
Results
Median follow-up was 12 months (range 6–18). Maximum detected acute skin toxicity was G0 41 %; G1 53 %; G2 6 %; G3 <1 %. With two G2–G3 acute skin toxicity events in the first stage and four in the second, the study fulfilled the requirements for the definition of the treatment approach under investigation as promising. Late skin toxicity was mild with no >G2 events. Cosmesis was good/excellent in 91 % of patients and fair/poor in 9 %. Quality of life was preserved over time, with the exception of fatigue, which was transiently increased.
Conclusions
Hypofractionated IM-WBRT with a SIB to the tumor bed delivered with TD provides consistent clinical results and it is able to reduce acute skin toxicity rate over conventionally fractionated and sequential boost tomotherapy-based IM-WBRT.
Similar content being viewed by others
References
Bantema-Joppe EJ, Schilstra C, de Bock GH, Dolsma WV, Busz DM, Langendijk JA, Maduro JH (2012) Simultaneous integrated boost irradiation after breast conserving surgery: physician-rated toxicity and cosmetic outcome at 30 months’ follow up. Int J Radiat Oncol Biol Phys 83(4):e471–e477
Barnett GC, Wilkinson JS, Moody A, Wilson CB, Twyman N, Wishart GC, Burnet NG, Coles CE (2012) Randomized controlled trial of forward-planned intensity modulated-radiotherapy for early breast cancer: interim results at 2 years. Int J Radiat Oncol Biol Phys 82(2):715–723
Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad WJ, Oei SB, Warlam-Rodenhuis CC, Pierart M, Colette L (2007) Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10 years results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 25(22):3259–3265
Borca VC, Franco P, Catuzzo P, Migliaccio F, Zenone F, Aimonetto S, Peruzzo A, Pasquino M, Russo G, La Porta MR, Cante D, Sciacero P, Girelli G, Ricardi U, Tofani S (2012) Does TomoDirect 3DCRT represent a suitable option for post-operative whole breast irradiation? A hypothesis-generating pilot study. Radiat Oncol 7:211
Cante D, Rosa La Porta M, Casanova-Borca V, Sciacero P, Girelli G, Pasquino M, Franco P, Ozzello F (2011) Accelerated hypofractionated adjuvant whole breast radiotherapy with concomitant photon boost after conserving surgery for early breast cancer: a prospective evaluation on 463 patients. Breast J 17(6):586–593
Cante D, Franco P, Sciacero P, Girelli G, Marra AM, Pasquino M, Russo G, Borca VC, Mondini G, Paino O, Barmasse R, Tofani S, Numico G, La Porta MR, Ricardi U (2013) Five-year results of a prospective case series of accelerated hypofractionated whole breast radiation with concomitant boost to the tumor bed after conserving surgery for early breast cancer. Med Oncol 30(2):518
Catuzzo P, Zenone F, Aimonetto S, Peruzzo A, Casanova Borca V, Pasquino M, Franco P, La Porta MR, Ricardi U (2012) Technical note: patient-specific quality assurance methods for TomoDirect(TM) whole breast treatment delivery. Med Phys 39(7):4073–4078
Chadha M, Woode R, Sillanpaa J, Lucido D, Boolbol SK, Kirstein L, Osborne MP, Feldman S, Harrison LB (2013) Early-stage breast cancer treated with 3-week accelerated whole-breast radiation therapy and concomitant boost. Int J Radiat Oncol Biol Phys 86(1):40–44
Coles C, Yarnold J, IMPORT Trials Management Group (2006) The IMPORT trials are launched (September 2006). Clin Oncol 18(8):587–590
Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5):1341–1346
Donovan E, Bleakley N, Denholm E, Evans P, Gothard L, Hanson J, Peckitt C, Reise S, Ross G, Sharp G, Symonds-Tayler R, Tait D, Yarnold J, Breast Technology Group (2007) Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 82(3):254–264
Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15 years survival: an overview of the randomized trials. Lancet 366(9503):2087–2106
Fayers PM, Aarson NK, Bjordal K, Curran D, Groenvold M, On behalf of the EORTC quality of life study group (1999) EORTC QLQ-C30 scoring manual, 2nd edn. EORTC, Brussels
Fiandra C, Filippi AR, Catuzzo P, Botticella A, Ciammella P, Franco P, Borca VC, Ragona R, Tofani S, Ricardi U (2012) Different IMRT solutions vs 3D-conformal radiotherapy in early stage Hodgkin’s Lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol 7:186
Fowler JF (2010) 21 years of biologically effective dose. Br J Radiol 83(991):554–568
Franco P, Ricardi U (2012) TomoDirect to deliver static angle tomotherapy treatments. J Nucl Med Radiat Ther 3:5
Franco P, Catuzzo P, Cante D, La Porta MR, Sciacero P, Girelli G, Casanova Borca V, Pasquino M, Numico G, Tofani S, Meloni T, Ricardi U, Ozzello F (2011) TomoDirect: an efficient means to deliver radiation at static angles with tomotherapy. Tumori 97(4):498–502
Franco P, Zeverino M, Migliaccio F, Sciacero P, Cante D, Casanova Borca V, Torielli P, Arrichiello C, Girelli G, Numico G, La Porta MR, Tofani S, Ricardi U (2013) Intensity-modulated adjuvant whole breast radiation delivered with static angle tomotherapy (TomoDirect): a prospective case series. J Cancer Res Clin Oncol 139(11):1927–1936
Freedman GM, Li T, Nicolaou N, Chen Y, Ma CC, Anderson PR (2009) Breast intensity-modulated radiation therapy reduces time spent with acute dermatitis for women of all breast sizes during radiation. Int J Radiat Oncol Biol Phys 74(3):689–694
Freedman GM, Anderson PR, Bleicher RJ, Litwin S, Li T, Swaby RF, Ma CM, Li J, Sigurdson ER, Watkins-Bruner D, Morrow M, Goldstein LJ (2012) Five-year local control in a phase II study of hypofractionated intensity modulated radiation therapy with an incorporated boost for early stage breast cancer. Int J Radiat Oncol Biol Phys 84(4):888–893
Freedman GM, White JR, Arthur DW, Li XA, Vicini F (2013) Accelerated fractionation with a concurrent boost for early stage breast cancer. Radiother Oncol 106(1):15–20
Harnett A (2010) Fewer fractions of adjuvant external beam radiotherapy for early breast cancer are safe and effective and can now be the standard of care. Why the UK’s NICE accepts fewer fractions as the standard of care for adjuvant radiotherapy in early breast cancer. Breast 19(3):159–162
Higher-dose radiation therapy or standard radiation therapy in treating patients with early-stage breast cancer that was removed by surgery. RTOG 1005. Located at www.cancer.gov/clinicaltrials/seach/view?cdrid=700069, Accessed 3 Sept 2013
Hijal T, Fourniez-Bodoz N, Castro-Pena P, Kirova YM, Zefkili S, Bollet MA, Dendale R, Campana F, Fourquet A (2010) Simultaneous integrated boost in breast conserving treatment of the breast: a dosimetric comparison of helical and three-dimensional conformal radiotherapy. Radiother Oncol 94(3):300–306
Holloway CL, Panet-Raymond V, Olivotto I (2010) Hypofractionation should be the new ‘standard’ for radiation therapy after breast conserving surgery. Breast 19(3):163–167
Hong L, Hunt M, Chui C, Spirou S, Forster K, Lee H, Yahalom J, Kutcher GJ, McCormick B (1999) Intensity-modulated tangential beam irradiation of the intact breast. Int J Radiat Oncol Biol Phys 44(5):1155–1164
James ML, Lehman M, Hider PN, Jeffery M, Hickey BE, Francis DP (2008) Fraction size in radiation treatment for breast conservation in early breast cancer. Cochrane Database Syst Rev 3:CD003860
Keller LM, Sopka DM, Li T, Klayton T, Li J, Anderson PR, Bleicher RJ, Sigurdson ER, Freedman GM (2012) Five-year results of whole breast intensity modulated radiation therapy for the treatment of early stage breast cancer: the Fox Chase Cancer Center Experience. Int J Radiat Oncol Biol Phys 84(4):881–887
Lievens Y (2010) Hypofractionated breast radiotherapy: financial and economic consequences. Breast 19(3):192–197
Mannino M, Yarnold JR (2009) Shorter fractionation schedules in breast cancer radiotherapy: clinical and economic implications. Eur J Cancer 45(5):730–731
Murai T, Shibamoto Y, Manabe Y, Murata R, Sugie C, Hayashi A, Ito H, Miyoshi Y (2013) Intensity-modulated radiation therapy using static ports of tomotherapy (TomoDirect): comparison with the TomoHelical mode. Radiat Oncol 8:68
National Cancer Institute Cancer Therapy Evaluation Program (2013) Common toxicity criteria for adverse events. 2013 Version 4.02. Available at http://ctep.cancer.gov. Accessed September 2013
Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139–144
Pignol JP, Olivotto I, Rakovitch E, Gardner S, Sixel K, Beckhman W, Vu TT, Truong P, Ackerman I, Paszat L (2008) A multicenter randomized trial of breast intensity modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 26(13):2085–2092
Poortmans P (2007) Evidence-based radiation oncology. Breast cancer. Radiother Oncol 84(1):84–101
Romestaing P, Lehingue Y, Carrie C, Coquard R, Montbarbon X, Ardiet JM, Mamelle N, Gerard JP (1997) Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol 15(3):963–968
Rose MA, Olivotto IA, Cady B, Koufman C, Osteen R, Silver B, Recht A, Harris JR (1989) Conservative surgery and radiation therapy for early stage breast cancer: long-term cosmetic results. Arch Surg 124(2):153–157
Schubert LK, Gondi V, Sengbush E, Westerly DC, Soisson ET, Paliwal BR, Mackie TR, Metha MP, Patel RR, Tomé WA, Cannon GM (2011) Dosimetric comparison of left-sided whole breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy and topotherapy. Radiother Oncol 100(2):241–246
Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1–10
Singla R, King S, Albuquerque K, Creech S, Dogan N (2006) Simultaneous-integrated boost intensity-modulated radiation therapy (SIBIMRT) in the treatment of early-stage left-sided breast carcinoma. Med Dosim 31(3):190–196
The START Trialists’ Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin P, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR (2008a) The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet Oncol 9(4):331–341
The START Trialists’ Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin P, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR (2008b) The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet 371(9618):1098–1107
van der Laan HP, Dolsma WV, Maduro JH, Korevaar EW, Hollander M, Langendijk JA (2007) Three-dimensional conformal simultaneously integrated boost technique for breast-conserving radiotherapy. Int J Radiat Oncol Biol Phys 68(4):1018–1023
Van Parijs H, Miedema G, Vinh-Hung V, Verbanck S, Adriaenssens N, Kerkhove D, Reynders T, Schuermans D, Leysen K, Hanon S, Van Camp G, Vincken W, Storme G, Verellen D, De Ridder M (2012) Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized trial. Radiat Oncol 7:80
Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, Shelley W, Grimard L, Bowen J, Lukka H, Perera F, Fyles A, Schneider K, Gulavita S, Freeman C (2010) Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362(6):513–520
Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, Haviland J, Bentzen S, Owen R (2005) Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomized trial. Radiother Oncol 75(1):9–17
Conflict of interest
We declare that we do not have any conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Franco, P., Zeverino, M., Migliaccio, F. et al. Intensity-modulated and hypofractionated simultaneous integrated boost adjuvant breast radiation employing statics ports of tomotherapy (TomoDirect): a prospective phase II trial. J Cancer Res Clin Oncol 140, 167–177 (2014). https://doi.org/10.1007/s00432-013-1560-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-013-1560-8